2021 Global Exosome Market Size, Forecast, Trials and Trends, Featuring Profiles of 107 Competitors Including Abbexa, Ltd., Abnova, Aruna Bio and Tavec Pharma
April 22, 2021 06:13 ET
|
Research and Markets
Dublin, April 22, 2021 (GLOBE NEWSWIRE) -- The "The Global Exosome Market - Market Size, Forecast, Trials, and Trends, 2021" report has been added to ResearchAndMarkets.com's offering. ...
Global Companion Diagnostics Partnering Analysis Report 2020: Latest Companion Diagnostics Agreements Announced in Life Science Since 2010
March 23, 2021 06:48 ET
|
Research and Markets
Dublin, March 23, 2021 (GLOBE NEWSWIRE) -- The "Global Companion Diagnostics Partnering Terms and Agreements 2010-2020" report has been added to ResearchAndMarkets.com's offering. The Global...
H-CYTE Bolsters Board of Directors With Appointment of Dr. Atta Behfar to its Board of Directors
July 30, 2019 08:00 ET
|
H-CYTE, Inc.
TAMPA, Fla., July 30, 2019 (GLOBE NEWSWIRE) -- H-CYTE Inc. (OTCQB: HCYT) (“H-CYTE” or the “Company”), the owner and operator of innovative medical technology products and services including Lung...
H-CYTE Bolsters Board of Directors With Appointment of Dr. Andre Terzic to Board of Directors
July 29, 2019 08:00 ET
|
H-CYTE, Inc.
TAMPA, Fla., July 29, 2019 (GLOBE NEWSWIRE) -- H-CYTE Inc. (OTCQB: HCYT) (“H-CYTE” or the “Company”), the owner and operator of innovative medical technology products and services including Lung...
Exosome Diagnostics and Therapeutics Market to Reach $180M by 2023
May 30, 2018 12:00 ET
|
BCC Research
WELLESLEY, Mass, May 30, 2018 (GLOBE NEWSWIRE) -- Many researchers are convinced that exosomes, which can transfer cytoplasmic ingredients, have unlimited potential in diagnostics and therapeutics,...
Exosome Diagnostics’ Second Prospective Validation Study of EPI to be Highlighted at American Urological Association (AUA) Annual Meeting Press Briefing in San Francisco, CA
May 17, 2018 12:47 ET
|
Exosome Diagnostics
Waltham, MA, May 17, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics’ novel urine-based prostate cancer liquid biopsy biomarker test, ExoDx™ Prostate(IntelliScore) or EPI, was selected out of 3000...
Exosome Diagnostics Continues to Expand Coverage Reach for its EPI Test
May 09, 2018 08:03 ET
|
Exosome Diagnostics
Waltham, MA, May 09, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. has continued to make significant progress in expanding contracts to provide laboratory services and ExoDx®...
Exosome Diagnostics Expands National Sales Team after Blockbuster Quarter with its Flagship Diagnostic, ExoDx Prostate®(IntelliScore) (EPI) Test
May 08, 2018 06:30 ET
|
Exosome Diagnostics
Waltham, MA, May 08, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. has expanded its urology salesforce within the United States after a successful first quarter commercial launch of ExoDx...
Recent Publication Highlights Proof-of-Concept Data Supporting the Diagnostic Potential of Phosphatidylserine-Positive Exosomes in Ovarian Cancer
February 09, 2017 08:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high...
Peregrine Licenses Novel Exosome-Based Cancer Detection and Monitoring Technology from UT Southwestern Medical Center
July 14, 2016 08:05 ET
|
Peregrine Pharmaceuticals Inc.
--New Technology Efficiently Builds on the Company’s Existing Phosphatidylserine (PS) Targeting Platform and Assay Development Capabilities-- --Stand Alone Program That Offers Significant...